The timeline for results can vary depending on the peptide used, an individuals metabolism, and lifestyle habits
Tirzepatide is a first-of-its-kind dual-action peptide that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors
Pancreatitis and Pancreatic Cancer: Debates and lawsuits center around the drug potentially raising pancreatitis risks, with caution also regarding long-term pancreatic cancer risks, especially in those with additional risk factors
It is our mission to help more people improve their quality of life through education and practical application of nutrition and exercise science
Certificate of Analysis Included With Every Order
In a Chinese phase II clinical trial, mazdutide decreased HbA1c by 1.41% to 1.67% in a dose-dependent manner, while a placebo decreased HbA1c by + 0.03% [102]